VOL 9 – NÚM 3 – DICIEMBRE 2024. NUEVOS MARCOS EN LA EVALUACIÓN DE TECNOLOGIAS SANITARIAS Y SUS EFECTOS EN MMHH
The value of medicines from a social perspective
Differential aspects of orphan drugs and their value from a social perspective
Modelo integrado y global de conocimiento en cáncer. Informe de resultados
Optimizing the involvement of EFCCA patients in medicines-related decision making
Excess mortality during the COVID-19 pandemic in Spain by non-COVID-19 causes of death
Libro blanco del cáncer gástrico y de unión gastroesofágica en España
Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)
Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)
Proyecto ESCRIBO. Estrategia para la Implementación de Cribado y Biomarcadores en el Sistema Nacional de Salud (SNS)
